logo
ProjectEnded

FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST

The status, timeline and source of this project. A free account opens every field.

Source: EU Funding & Tenders Portal

Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15

Status
Closed
Sector
Power Generation (CCGT)
Location
Denmark
Updated
22 Jul 2026
Source
EU Funding & Tenders Portal

ConstructChat

Ask ConstructChat about FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “FIRST INSTANT, OFF-THE-LAB AND USER-FRIENDLY BLOOD GROUPING TEST” is an infrastructure initiative in the Power Generation (CCGT) sector, located in Denmark. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Participants

Not available for this record.

Status

Original status

ended

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Despite being eradicated from the developed world, the Rhesus Disease or HDFN (Hemolytic Disease of the Fetus and Newborn), a disease where the immune system from the mother attacks the red blood cells from their babies, still kills 141,000 children and mothers in developing regions every year. Deaths that could be easily prevented by screening pregnant women for their RhD factor type. Although 15% of RhD(-) women are at risk, 220 million women in developing countries should be tested, since the majority do not know their RhD factor type. At Eldon Biologicals AS (a Danish company created in 2002), we are a profitable company that has already sold millions of EldonCards (a pioneering off-the-lab dry format grouping test) in more than 44 countries and has built a well-established worldwide network of customers and distributors. We are part of the influential International Federation of Gynecology and Obstretics (FIGO) and founding member of CURhE, an international initiative to stop HDNF. Now, we are moving one step further from EldonCards overcoming its limitations to erase HDNF from developing countries. To do so, we have created ABOPEN, a user-friendly off-the-lab grouping test that can be stored for up to 24 months at 37C and works similarly to pregnancy tests, identifying the RhD factor type in just 1 minute and a single-step procedure. ABOPEN can be performed outside a laboratory setting (does not need electricity) by non-trained personnel, while keeping its affordability (it costs just €4), precision and accuracy. ABOPEN has also a sizeable market in developed countries, as an instant and easy to use device to find out about blood grouping for urgent transfusions (accidents, hospitals, military) or just personal information. By end of 2025, we expect to generate €8 million in turnover (ROI of 2.2), while creating 7 new jobs for the company.

Location

Country

Denmark

Source

Source

EU Funding & Tenders Portal

URL

More Details

Record type

Project

Sector

Power Generation (CCGT)

Article published date

2026-02-15

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project